Korea Green Light For Pfizer’s Novel Breast Cancer Drug
Pfizer's first-in-class breast cancer drug Ibrance is set to debut in South Korea following a regulatory approval and will offer a new option for the growing number of patients in the country.
You may also be interested in...
Data to be presented at ASCO in June suggests Pfizer’s Ibrance has a good shot at maintaining a leadership position in the category as competitors Lilly and Novartis step closer to the market.
Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.